SPECIAL INVESTIGATION FOR ABRYSVO IN INDIVIDUALS AGED 60 YEARS OR OLDER

A Study on the Immune Response, Safety and the Occurrence of Respiratory Syncytial Virus (RSV)-Associated Respiratory Tract Illness After Administration of RSV OA Vaccine in Adults 60 Years and Older

NCT06551181 ·Status: COMPLETED ·Phase: PHASE3

A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and Above

NCT05590403 ·Status: COMPLETED ·Phase: PHASE3

Safety and Immunogenicity of RSVpreF Coadministered With SIIV in Adults ≥65 Years of Age

NCT05301322 ·Status: COMPLETED ·Phase: PHASE3

Safety and Efficacy of BARS13 in the Elderly

NCT04681833 ·Status: COMPLETED ·Phase: PHASE2

A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and Above

NCT06389487 ·Status: COMPLETED ·Phase: PHASE3

A Phase 2 Study to Describe the Safety and Immunogenicity of Respiratory Syncytial Virus Vaccine IN006 in Healthy Participants Aged 60 Years and Older

NCT07128121 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older

NCT04908683 ·Status: COMPLETED ·Phase: PHASE3

Phase I, First-In Human Study to Evaluate Safety and Tolerability of EuRSV in Healthy Adults Aged Between 19 Years and 80 Years

NCT06216093 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Study of a Respiratory Syncytial Virus Candidate Encapsulated in a Lipid Nanoparticle Based Formulation in Adults Aged 18 to 50 Years and 60 Years and Older

NCT05639894 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age

NCT07117487 ·Status: COMPLETED ·Phase: PHASE3

A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy Adults

NCT05966090 ·Status: COMPLETED ·Phase: PHASE3

Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate

NCT06134648 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Study to Evaluate the Efficacy of an RSV F Vaccine in Older Adults

NCT02608502 ·Status: COMPLETED ·Phase: PHASE3

A Study to Evaluate the Safety of the Respiratory Syncytial Virus Vaccine MEDI7510 in Older Adults

NCT02115815 ·Status: COMPLETED ·Phase: PHASE1

Evaluating the Infectivity, Safety and Immunogenicity of Respiratory Syncytial Virus Vaccines, RSV 6120/∆NS1 and RSV 6120/F1/G2/∆NS1, in RSV-Seropositive Children and RSV-Seronegative Infants and Children

NCT03596801 ·Status: COMPLETED ·Phase: PHASE1

A Study of IVX-A12 in Adults Participants

NCT06481579 ·Status: COMPLETED ·Phase: PHASE2

RSV Immunogenicity Study in the Elderly (RISE)

NCT07203365 ·Status: RECRUITING ·Phase: PHASE3

Study to Evaluate the Safety and Immune Response of an Investigational Vaccine for the Prevention of RSV (Respiratory Syncytial Virus) and (hMPV) Human Metapneumovirus Infection in Participants Aged 60 to 75 Years

NCT06583031 ·Status: COMPLETED ·Phase: PHASE1

A Study of Adenovirus Serotype 26.Respiratory Syncytial Virus.Pre-Fusion F (Ad26.RSV.preF)-Based Vaccine for Prevention of Respiratory Syncytial Virus (RSV) Mediated- Lower Respiratory Tract Disease (LRTD) in Japanese Participants

NCT05242432 ·Status: TERMINATED ·Phase: PHASE3

Post-Marketing Non-Acute Safety Study in Japan After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons at High Risk of Severe COVID-19

NCT05894590 ·Status: COMPLETED

A Study on the Safety and Immune Response to an mRNA-based RSV Investigational Vaccine in Healthy Adults Aged 18-45 Years

NCT06573281 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy Adult Aged 18 Years and Above

NCT06645665 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Study of a Respiratory Syncytial Virus/Human Metapneumovirus/Parainfluenza Virus Type 3 Vaccine Candidate in Adults Aged 60 Years and Older

NCT06604767 ·Status: COMPLETED ·Phase: PHASE1

A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Older Adults in Korea

NCT06593587 ·Status: COMPLETED ·Phase: PHASE3

A Study to Evaluate the Immunogenicity and Safety of a Recombinant Respiratory Syncytial Virus Vaccine in Older Adults Aged 60 Years and Older

NCT07208461 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2